SHENZHEN, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Tongjitang
Chinese Medicines Company (the "Company" or "Tongjitang") (NYSE:
TCM), a leading specialty pharmaceutical company focusing on the
development, manufacturing, marketing and selling of modernized
traditional Chinese medicine in China, today announced that on September 3, 2010, Mr. Charles Wang submitted his resignation as Chief
Financial Officer for personal reasons and not as a result of any
disagreement with the Company regarding financial or accounting
practices. The resignation will be effective on December 2, 2010.
Mr. Charles Wang is expected to
stay with the company until December. The Company has commenced an
executive search in order to find a replacement.
Xiaochun Wang, Tongjitang's Chief
Executive Officer and Chairman of the Board of Directors, stated,
"On behalf of the Board, management, and employees of our company,
I'd like to thank Mr. Charles Wang
for his dedication and contribution to Tongjitang over the past two
years and wish him all the best on his future endeavors."
About Tongjitang Chinese Medicines Company
Tongjitang Chinese Medicines Company, through its operating
subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution,
Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company
Limited, Qinghai Pulante, Anhui Jingfang and Gui Liqour Ltd., is a
vertically integrated specialty pharmaceutical company focused on
the development, manufacturing, marketing and selling of modernized
traditional Chinese medicine in China. Tongjitang's principal executive
offices are located in Shenzhen,
China.
Tongjitang's flagship product, Xianling Gubao, is the leading
traditional Chinese medicine for the treatment of osteoporosis in
China as measured by sales in
Renminbi. In addition to Xianling Gubao, the Company manufactures
and markets 35 other modernized traditional Chinese medicine
products and 36 western medicines. Please visit
http://www.tongjitang.com for more information.
For more information, please contact:
ICR, Inc.
Ashley M. Ammon or Christine Duan
Phone: +1-203-682-8200 (Investor Relations)
SOURCE Tongjitang Chinese Medicines Company
Copyright t. 8 PR Newswire